KOSPIBiotech & Pharma377740

BioNote

₩4,435▼ 1.22%2026-11-18 close
Market Cap
₩451.9B
Turnover
₩300M
Volume
60K
Shares out.
100M
PER
—
PBR
0.3×
EPS
-₩2,065
Dividend Yield
5.04%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩228 per share · Prices as of the 2026-11-18 close

01

Report overview

Operating profit rising, net losses recurring

Animal diagnostics growth has restored operating profit since 2024, but attributable net income swung into losses for FY2025 and in the third quarter of 2026.

  1. 1

    Operating profit turned to KRW 12.2 billion in 2024 and rose to KRW 16.7 billion in 2025, up 36.8%.

  2. 2

    The attributable net loss of KRW 87.5 billion in 2025 reversed the attributable net profit of KRW 55.3 billion in 2024.

  3. 3

    The attributable net loss for Q3 2026 was KRW 65.3 billion, and the total attributable net loss over the last four quarters was KRW 209 billion.

  4. 4

    The debt ratio was 3.0% at end-2025, with total liabilities of KRW 44.6 billion and total equity of KRW 1.51 trillion, a relatively light financial burden.

  5. 5

    Whether the growth in Vcheck F sales translates into improved earnings is the next point to check.

02

Business structure

BioNote runs two businesses: an animal diagnostics unit that sells veterinary test products, and a life science (bio contents) unit that supplies intermediate products and raw materials based on its recombinant antigen and antibody manufacturing technology.

Through the first nine months of 2023, animal diagnostics accounted for 71% of revenue and bio contents for 29%, according to a February 2024 equity research report.

The core animal diagnostics lineup comprises the Rapid veterinary test kits, the Vcheck F fluorescence immunoassay analyzer, the Vcheck M point-of-care molecular analyzer, the Vcheck C biochemistry analyzer and the Vcheck H hematology analyzer.

In its preliminary release of May 13, 2026, the company said cumulative global sales of Vcheck F were approaching 25,000 units.

The life science unit's sales rose through intermediate products and raw materials supplied to affiliated companies, and the company said profitability improved through cost cuts and operating efficiency.

Its main customers are distributors and affiliated companies in each country, and the same research report recorded a supply agreement with a large distributor serving animal hospitals in the United States and globally.

The company says it is widening its range from immunoassays into biochemistry, hematology, urine and molecular testing. In its preliminary first-half release of August 6, 2026, it cited entry into the automated CLIA market and an AI-based diagnostics platform as portfolio diversification steps.

Because the revenue base is weighted toward animal diagnostics, demand for that product family largely sets the direction of total sales.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩29.5B₩4.8B16.3%
2025Q4₩28B₩800M3.0%
2026Q1₩32.6B₩6.3B19.5%
2026Q2₩36.4B₩8.5B23.3%
2026Q3₩32.1B₩8B24.9%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩479.7B₩295.4B₩307.8B61.6%19.2%9.8%
2023₩90.1B-₩47B-₩20.5B−52.2%−1.3%2.3%
2024₩102.8B₩12.2B₩55.3B11.9%3.4%3.8%
2025₩118.3B₩16.7B-₩87.5B14.1%−5.8%3.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual revenue fell from KRW 479.7 billion in 2022 to KRW 90.1 billion in 2023, a decline of 81.2%, and the company posted an operating loss of KRW 47 billion in 2023. Revenue recovered to KRW 102.8 billion in 2024, up 14.1%, and operating profit turned to KRW 12.2 billion.

In 2025 revenue reached KRW 118.3 billion, up 15.1%, and operating profit rose to KRW 16.7 billion, up 36.8%, extending the increase to two consecutive years. The operating margin moved from 61.6% in 2022 to -52.2% in 2023, then recovered to 11.9% in 2024 and 14.1% in 2025.

The 2022 result was driven largely by the bio contents unit, which had COVID diagnostics-related revenue, according to a February 2024 research report. The company attributed the 2023 revenue decline to weak results after the COVID endemic transition.

The company said 2024 revenue, excluding the pandemic period, exceeded KRW 100 billion for the first time since its founding. It attributed the 2025 operating profit increase to new product launches, higher sales of existing products and better cost of sales.

Attributable net loss and net loss were both KRW 87.5 billion in 2025, and the company cited losses from equity-method affiliates among the factors behind the swing into loss.

Quarterly figures show a wide gap between operating profit and net income: in Q1 2026 operating profit was KRW 6.35 billion while attributable net income was KRW 41.3 billion, in Q2 operating profit was KRW 8.46 billion against attributable net income of KRW 9.07 billion, and in Q3 operating profit was KRW 7.99 billion against an attributable net loss of KRW 65.3 billion.

Pre-tax loss in Q3 2026 was KRW 75.39 billion, which means non-operating losses far exceeded operating profit. Cumulative January to September 2026 revenue was KRW 101.0 billion, up 11.8%, and operating profit was KRW 22.79 billion, up 43.6%, according to press coverage of the third-quarter report. Operating cash flow fell from KRW 57.9 billion in 2024 to KRW 14.4 billion in 2025.

05

Industry analysis

The animal diagnostics market is growing on the back of rising pet households and the broader humanization of pets, according to a corporate commentary on a securities information service. Livestock in vitro diagnostics is described as maintaining steady growth supported by rising national disease-control budgets.

BioNote's position in the cycle can be seen in three phases: the COVID-driven peak, the contraction and the recovery. Revenue was KRW 479.7 billion in 2022, when COVID diagnostics sales were significant, and fell to KRW 90.1 billion in 2023 after the endemic transition.

Sales recovered from 2024 as product demand returned, reaching KRW 118.3 billion in 2025, which is still well below the 2022 level. On competition, the company positions itself on a broad diagnostic solution spanning immunoassays, biochemistry, hematology, urine and molecular testing.

Overseas sales run through distributors and overseas subsidiaries, so the company says the reach of its distribution network determines its market position. The life science unit is moving toward higher profitability through cost reduction and operating efficiency.

Entry into the animal antibody therapeutics market is a new growth driver the company has cited, but its contribution to earnings has not yet appeared in reported figures.

06

Outlook

The company said in its May 2026 preliminary first-quarter release that it intends to keep expanding its share of the global animal diagnostics market.

In its August 6, 2026 preliminary first-half release, it cited entry into the automated CLIA market and an AI-based diagnostics platform as steps in portfolio diversification.

It plans to combine the independent capabilities of its overseas subsidiaries with a diversified global distribution network to extend its reach.

In a February 2026 report, the company said it would strengthen its partnership with large corporate veterinary hospital groups, which it described as central to the US veterinary market. It also said it would enter the animal antibody therapeutics market to secure a new growth engine.

On shareholder returns, it decided in February 2026 to cancel 650,000 treasury shares, with the cancellation scheduled for March 6, 2026, and it also decided on a year-end cash dividend.

Quarterly revenue in 2026 was KRW 32.6 billion, KRW 36.4 billion and KRW 32.1 billion for Q1 to Q3, peaking in Q2 before falling 11.8% quarter on quarter in Q3. Operating profit in Q3 was KRW 7.99 billion, up year on year, but net income continues to depend on non-operating items.

The next checkpoint is therefore whether overseas partnerships and new products lift the operating margin. Results from the new businesses can be checked numerically in regular reports from 2027 onward.

07

Valuation

PER
—
PBR
0.3×
ROE
-13.2%
EPS
-₩2,065
BPS
₩14,444
Dividend per share
₩228

Because the total attributable net loss over the last four quarters was KRW 209 billion, the price-to-earnings ratio cannot be calculated. The price-to-book ratio sits well below 1x, meaning market capitalization is low relative to total equity of KRW 1.51 trillion.

A share price well below book value also reflects doubts over whether the balance sheet translates into earnings power while attributable net income alternates between profit and loss.

Because the dividend yield rises as the share price falls, dividend continuity depends on operating cash flow of KRW 14.4 billion in 2025 and the direction of attributable net income.

The pattern since the 2024 swing to profit, followed by a 2025 loss, a Q1 2026 profit and a Q3 2026 loss, means any multiple needs to be read alongside the quarterly trend. Earnings multiples measured against a period of stable profit are difficult to apply directly to the current loss-making phase.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Animal diagnostics recovery and wider operating profit

Revenue fell to KRW 90.1 billion in 2023, then rose to KRW 102.8 billion in 2024 and KRW 118.3 billion in 2025, increasing for two consecutive years. Operating profit turned to KRW 12.2 billion in 2024 and rose to KRW 16.7 billion in 2025.

Operating profit for Q1 to Q3 2026 was KRW 6.35 billion, KRW 8.46 billion and KRW 7.99 billion, each up year on year.

Financial capacity and shareholder return policy

Total equity at end-2025 was KRW 1.51 trillion, total liabilities were KRW 44.6 billion and the debt ratio was 3.0%. The company decided to cancel 650,000 treasury shares, with a scheduled cancellation date of March 6, 2026, and also decided on a year-end dividend. It describes shareholder returns as a core management principle.

Global distribution and new product pipeline

The company said in its May 2026 preliminary release that cumulative global sales of Vcheck F were approaching 25,000 units. Entry into the automated CLIA market and an AI-based diagnostics platform were presented as next steps in its August 2026 first-half release.

Strengthening its partnership with large US corporate veterinary hospital groups was also reported as a company plan.

09

Bear factors

Recurring net losses

The attributable net loss in 2025 was KRW 87.5 billion, a swing from profit in 2024. Q3 2026 added an attributable net loss of KRW 65.3 billion, bringing the four-quarter total to KRW 209 billion. Quarterly operating profit stayed in the KRW 6 billion to 8 billion range, yet net results did not follow.

Revenue base shrunk from the pandemic peak

Revenue fell from KRW 479.7 billion in 2022 to KRW 118.3 billion in 2025, and although it is recovering, it remains far below the earlier peak. Q3 2026 revenue was KRW 32.1 billion, down 11.8% from the prior quarter.

With animal diagnostics at 71% of revenue in 2023, the company is sensitive to demand shifts in that product family.

Volatile operating cash flow

Operating cash flow went from KRW -4.19 billion in 2023 to KRW 57.9 billion in 2024 and then fell to KRW 14.4 billion in 2025. Equity-method losses cited for the 2025 swing into loss are accounting items that do not directly involve cash outflows. For dividend continuity, the decline in cash generation is a variable to watch.

10

Risk factors

Affiliate and non-operating earnings volatility

The company cited equity-method losses among the factors behind the KRW 87.5 billion net loss in 2025. Q3 2026 pre-tax loss of KRW 75.39 billion far exceeded operating profit of KRW 7.99 billion.

Because operating results and net income move separately, operating profit gains alone do not indicate the direction of net income.

Product concentration and post-pandemic normalization

Animal diagnostics made up 71% of revenue in 2023, with Vcheck F and the Rapid kit line as core products. The company experienced a sharp revenue decline after the COVID-related sales period of 2022 ended. Demand shifts in a single product family flow directly into total results.

Overseas distribution and new business execution

Customers are mainly overseas distributors and affiliates, so results depend on partner performance and contract terms. Automated CLIA, the AI-based platform and animal antibody therapeutics are new businesses whose contribution is not yet visible in reported results. Delays in executing them could slow growth in the current product lines.

11

What to watch next

  1. Around late February 2027

    Preliminary FY2026 results. The FY2025 preliminary results were released on February 25, 2026. Whether Q4 2026 operating profit and attributable net income reconcile with the annual trend is the point to check.

  2. End of March 2027

    FY2026 annual report. The annual breakdown of attributable net income, equity-method results and operating cash flow will be reported here. Whether the gap between operating profit and net income narrows is the key item.

  3. Mid-May 2027

    Q1 2027 preliminary results and quarterly report. Q1 2026 was released as preliminary on May 13. Whether animal diagnostics sales and operating profit keep growing, and whether net income returns to profit, are the points to check.

  4. Mid-August 2027

    H1 2027 semi-annual report. The 2026 semi-annual report was filed on August 13. Progress in automated CLIA and the share of revenue from overseas subsidiaries are indicators of how the new businesses are performing.

12

Overall view

BioNote has increased operating profit since swinging to profit in 2024, driven by its animal diagnostics product lines, and operating profit for Q1 to Q3 2026 was each up year on year.

Attributable net income, however, has alternated into losses, with a 2025 net loss of KRW 87.5 billion and a Q3 2026 loss of KRW 65.3 billion, and the four-quarter attributable net loss totals KRW 209 billion.

Strengths include the recovery in operating profit, a light financial burden with a 3.0% debt ratio, and shareholder returns through treasury share cancellation and dividends.

Weaknesses include the volatility of equity-method and non-operating results, revenue that has shrunk relative to 2022, and lower operating cash flow. On valuation, the price-to-earnings ratio cannot be calculated because of losses, and the price-to-book ratio sits well below 1x.

The stock is currently in a phase where operating recovery and net income volatility coexist. The next checkpoints are the gap between operating profit and attributable net income in the FY2026 annual report and the Q1 2027 results.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. ssl.pstatic.net
  2. kormedi.com
  3. comp.wisereport.co.kr
  4. pharm.edaily.co.kr
  5. m.pharmstock.co.kr
  6. markets.hankyung.com
  7. m.news.nate.com
  8. m.news.nate.com
  9. pharm.edaily.co.kr
  10. getnews.co.kr
  11. m.news.nate.com
  12. mt.co.kr
  13. mydaily.co.kr
  14. supple.kr
  15. hankyung.com
  16. dailymedi.com
  17. yakup.com
  18. saramin.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis